View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 18, 2021

Hologic concludes acquisition of Mobidiag for $808m

Hologic plans to steer the growth of Mobidiag's platform Novodiag by investing in assay development. 

Hologic has completed the acquisition of Finnish-French molecular diagnostic test developer Mobidiag for an enterprise value of nearly $808m.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

In April, Hologic entered a definitive agreement to acquire Mobidiag.

Mobidiag develops near-patient, molecular diagnostic instruments and tests for acute care conditions such as gastrointestinal, respiratory infections, antimicrobial resistance management and healthcare linked infections.

Last year, Mobidiag earned revenues of nearly $42m.

Its testing platforms, Amplidiag and Novodiag, provide results in between 50 minutes and two hours.

The Novodiag platform combines real-time polymerase chain reaction (PCR) and microarray expertise to offer advanced multiplexing.

Multiplexing aids in detecting various pathogens from a single sample, simplifying workflows for labs and delivering quick results to doctors.

Hologic plans to invest in assay development to further grow the Novodiag platform.

Owing to the investment, Hologic estimates the acquisition to be about $0.10 dilutive to its non-GAAP earnings per share in fiscal 2022, slightly dilutive in 2023 and accretive afterwards.

The acquisition will support the worldwide growth of Mobidiag’s differentiated molecular platform, which is user-friendly with multiplex abilities and quick turnaround times.

For Hologic, the deal will bolster its global and diagnostics businesses.

Hologic international group president Jan Verstreken said: “Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader.

“Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”

Hologic funded the transaction with cash on hand and by borrowing on its current line of credit.

In March, Hologic acquired molecular diagnostic assays and epigenetics products manufacturer Diagenode in a deal worth approximately $159m.

Diagenode is expected to grow Hologic’s diagnostic business across test menu and customer segments as well as geographically.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network